Team:USTC CHINA/Project/Overview

From 2013.igem.org

(Difference between revisions)
Line 56: Line 56:
<div class="content" align="center">
<div class="content" align="center">
<div class="conbar1">
<div class="conbar1">
-
<div id="breadcrumb"><a href="https://2013.igem.org/Team:USTC_CHINA">Home</a> &gt; <a href="https://2013.igem.org/Team:USTC_CHINA/Project/Overview">project</a> &gt; <a href="https://2013.igem.org/Team:USTC_CHINA/Project/Overview">overview</a></div></div>
+
<div id="breadcrumb"><a href="https://2013.igem.org/Team:USTC_CHINA">Home</a> &gt; <a href="https://2013.igem.org/Team:USTC_CHINA/Project/Overview">Project</a> &gt; <a href="https://2013.igem.org/Team:USTC_CHINA/Project/Overview">Overview</a></div></div>
<div class="conbar2">
<div class="conbar2">
<div class="leftbar" align="left">
<div class="leftbar" align="left">

Revision as of 19:48, 25 September 2013

Overview

T-VACCINE——A vaccine that can initiate immune response by penetrating the skin with the aid of transdermal peptide. From now on, injections are simply history! Based on the theory of user-friendly, a special group of engineering bacteria which produce T-VACCINE is used to create a brand-new "band-aid" that can serve as a guardian of our health .
*****配张图吧@邵雪盈***** We have found a kind of transdermal peptide TD-1——a magical molecule that not only enhances the permeability of the skin but also draw filamentous bacteriophages into the skin. By combining the gene fragments of antigen, immune adjuvant LTB and Luman-recruiting factor TNLFα with that of the transdermal peptide, our team got the permeable fusion protein. In order to obtain large amount of extracelluar protein, we chose bacillus subtilis WB800N as our expression engineering bacteria. At last, the universality of our experimental method is verified by the adoption of various antigen of existing vaccine, such as HBsAg, PA and AG85B.

Project contains

For in situ transdermal vaccine is real a giant project, we devide it into four lab parts. And we expect to achieve following goals.

Antigen

As the main part of T-vaccine, TD-1 is fused with antigen protein, so it can penetrate the skin and present antigen. We had designed there kinds of vaccine, which are against hepatitis B, TB and anthrax. Our ELISA test and mice test had proved their antigenicity and immunogenicity,thereby proving that T-vaccine can be generally used.

adjuvant

Similar with traditional injection vaccine, adjuvant should be added into vaccine to ensure immunity. We fused TD-1 with LTB. LT has adjuvant activity and can assist foreign antigen to induce the body to produce systemic immune response. The B submit of LTB protein has no toxic effect and it also works.

TNFα

TNFα can recruit Langerhans cell(LC), which work as antigen-presenting cells around epidermis, and improved LC’s transmission to adjacent lymph node. Because this circuit is quite similar with 1# and 2# ,while its effect might be difficult to certified, so we delay the schedule of this part. 3# is the only circuit which has not been built or tested.

Device

*****邵雪盈速度来救******

project

Retrieved from "http://2013.igem.org/Team:USTC_CHINA/Project/Overview"